Применение Ксеникала в клинической практике

ожирение, лечение, питание, физическая активность, орлистат.

1. Бутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению //Русский медицинский журнал. – 2001. – Т. 9. – №. 2. – С. 56-60. [Butrova S A Metabolicheskiy sindrom: patogenez, klinika, diagnostika, podkhody k lecheniyu. Russkiy meditsinskiy zhurnal. 2001; 9(2): 56-60. (In Russ).].

2. Мкртумян А.М. Ксеникал в комплексной терапии метаболического синдрома // Русский медицинский журнал. — 2001. – Т. 9. – №. 2.— С. 72–73. [Mkrtumyan AM. Ksenikal v kompleksnoy terapii metabolicheskogo sindroma. Russkiy meditsinskiy zhurnal. 2001; 9(2): 72–73. (In Russ).]

3. Чигарькова О.В. Состояние костной ткани у женщин с ожирением в постменопаузе. Влияние снижения массы тела на минеральную плотность кости и показатели костного метаболизма : дис. … канд. мед. наук. — М., 2008. — С. 138. [Chigar'kova OV. Sostoyanie kostnoy tkani u zhenshchin s ozhireniem v postmenopauze. Vliyanie snizheniya massy tela na mineral'nuyu plotnost' kosti i pokazateli kostnogo metabolizma.[dissertation] Moscow; 2008. (In Russ)]

4. Butrova S., Ershova E., Ilyin A. et al. Orlistat influence on clinical, hormonal and metabolic parameters of obese patients with high risk of type 2 diabetes and cardiovascular diseases. Int. J. Obes. 2004; 28: 115.

5. Cocco G, Pandolfi S, Rousson V. Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic Syndrome. Heart Drug. 2005;5(2):68-74. doi: 10.1159/000083662

6. Colditz GA. Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women. Annals of Internal Medicine. 1995;122(7):481. doi: 10.7326/0003-4819-122-7-199504010-00001

7. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat. Jama. 1999;281(3):235. doi: 10.1001/jama.281.3.235

8. Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA, et al. The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study. Current Medical Research and Opinion. 2004;20(9):1393-401. doi: 10.1185/030079904125004466

9. Dimitrov D, Bohchelian H, Koeva L. Effect of Orlistat on Plasma Leptin Levels and Risk Factors for the Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 2005;3(2):122-9. doi: 10.1089/met.2005.3.122

10. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4

11. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Current Medical Research and Opinion. 2005;21(12):1997-2006. doi: 10.1185/030079905x75078

12. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity. 2000;24(3):306-13. doi: 10.1038/sj.ijo.0801128

13. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. International Journal of Obesity. 2001;25(8):1154-60. doi: 10.1038/sj.ijo.0801639

14. Hauptman J. Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Archives of Family Medicine. 2000;9(2):160-7. doi: 10.1001/archfami.9.2.160

15. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Archives of Internal Medicine. 2000;160(9):1321. doi: 10.1001/archinte.160.9.1321

16. Hill JO. Obesity and the Environment: Where Do We Go from Here? Science. 2003;299(5608):853-5. doi: 10.1126/science.1079857

17. Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., ... & Aronne, L. J. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. The American journal of clinical nutrition. 1999; 69(6), 1108-1116.

18. Holecki M, Zahorska-Markiewicz B, Nieszporek T, Mizia-Stec K, Olszanecka-Glinianowicz M, Żak-Gołąb A, et al. Impact of the mass-reductive therapy with orlistat on 25-(OH)-D 3 and PTH concentration in sera of obese, menopausal women. Endokrynologia Polska. 2005;56(3):240-5.

19. Krempf M., Laville M., Basdevant A. et al. Effect of orlistat on NCEP ATP-III-defined metabolic syndrome in obese or overweight patients: meta-analysis from 20 randomised double-blind studies worldwide. Obes. Rev. 2005; 1: 166.

20. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2003;27(1):155-61. doi: 10.2337/diacare.27.1.155

21. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL – Primary Health Care Trial. Diabetes, Obesity and Metabolism. 2005;7(1):21-7. doi: 10.1111/j.1463-1326.2004.00428.x